Voting Results from DIAGNOS Inc. Shareholder Meeting
DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) has recently announced the results of its annual shareholder meeting. The company, based in Quebec, is a frontrunner in leveraging Artificial Intelligence (AI) for the early detection of critical health issues. The meeting was held to discuss corporate governance and various essential matters concerning the future of DIAGNOS.
New Directors Elected
During the meeting, shareholders elected Mr. André Larente, Mr. Robert Dunn, Mr. Michael Braeuel, and Mr. Philippe Couillard as directors. These individuals are entrusted with guiding the company until the next annual meeting, ensuring that DIAGNOS continues on its innovative path in health technology next year.
Appointment of Auditors
Grant Thornton LLP has been appointed as the auditor for DIAGNOS for the upcoming financial year. This appointment is crucial for maintaining transparency and accountability as the company continues to grow its operations and technology.
Stock Options Granted
In a significant move to align the interests of its directors with those of shareholders, DIAGNOS has announced the granting of 1,100,000 stock options. This grant replaces 600,000 stock options that expired recently and includes the replacement for another set expiring shortly. These options have an exercise price set at $0.26 per share and will vest at 50% per year beginning in the first year. This strategic decision reflects DIAGNOS's commitment to retaining talented leadership while fostering shareholder value.
Regulatory Compliance
It is worth noting that the stock options granted are subject to compliance with regulatory requirements, including acceptance by the TSX Venture Exchange. DIAGNOS aims to ensure that all provisions are met efficiently.
About DIAGNOS Inc.
DIAGNOS is dedicated to revolutionizing healthcare with its powerful FLAIRE Artificial Intelligence platform, which enables rapid development of applications such as CARA (Computer Assisted Retina Analysis). This innovative tool enhances retinal images for more accurate analysis, facilitating real-time screening for a large volume of patients at a lower cost. The technology reinforces DIAGNOS's role in preventative healthcare strategies.
The value of DIAGNOS's technology lies in its efficiency; the ability to detect health problems early can significantly reduce treatment costs and improve patient outcomes. As the demand for healthcare solutions evolves, DIAGNOS is at the forefront, with a vision driven by cutting-edge AI.
Contact Information
For more insights into DIAGNOS and its innovative healthcare solutions, you can reach:
Mr. André Larente, President
DIAGNOS Inc.
Phone: 450-678-8882 ext. 224
Frequently Asked Questions
What was the primary outcome of the DIAGNOS meeting?
The shareholders elected four directors and appointed Grant Thornton LLP as the auditor for the upcoming year.
When will the newly elected directors serve until?
They will serve until the closing of the next annual meeting of shareholders.
How many stock options were granted, and what is their price?
DIAGNOS granted 1,100,000 stock options at an exercise price of $0.26 per share.
What is the role of the FLAIRE platform in DIAGNOS?
FLAIRE supports the early detection of critical health issues through advanced AI technologies, offering applications like CARA.
Who can be contacted for more information about DIAGNOS?
Mr. André Larente, President of DIAGNOS, is available for inquiries at the provided phone number.
